FY2024 EPS Estimates for Glaukos Increased by Zacks Research

Glaukos Co. (NYSE:GKOS) – Zacks Research boosted their FY2024 EPS estimates for shares of Glaukos in a report released on Monday, November 25th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings of ($1.98) per share for the year, up from their prior forecast of ($2.32). The consensus estimate for Glaukos’ current full-year earnings is ($1.96) per share. Zacks Research also issued estimates for Glaukos’ Q4 2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.22) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.23) EPS.

Several other equities research analysts also recently weighed in on GKOS. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Stifel Nicolaus upped their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC raised their price objective on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Piper Sandler set a $140.00 target price on Glaukos in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. increased their price target on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $135.45.

Glaukos Trading Up 1.4 %

Shares of GKOS stock opened at $142.68 on Thursday. The firm has a market capitalization of $7.87 billion, a PE ratio of -47.25 and a beta of 1.02. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos has a 1 year low of $59.58 and a 1 year high of $146.86. The stock has a fifty day moving average of $133.15 and a two-hundred day moving average of $124.27.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. During the same period in the previous year, the firm posted ($0.50) earnings per share. The business’s revenue was up 23.9% on a year-over-year basis.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This represents a 2.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

Institutional Trading of Glaukos

A number of hedge funds have recently modified their holdings of the business. Franklin Resources Inc. grew its holdings in shares of Glaukos by 80.1% during the third quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier’s stock valued at $2,031,000 after buying an additional 6,948 shares in the last quarter. Tidal Investments LLC grew its stake in Glaukos by 83.1% during the 3rd quarter. Tidal Investments LLC now owns 14,908 shares of the medical instruments supplier’s stock valued at $1,942,000 after acquiring an additional 6,767 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Glaukos during the 3rd quarter valued at about $258,000. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Glaukos by 84.3% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 28,470 shares of the medical instruments supplier’s stock valued at $3,709,000 after purchasing an additional 13,019 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Glaukos by 6.0% in the third quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier’s stock worth $152,722,000 after purchasing an additional 66,134 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.